Brought to you by:
New analysis of chronic limb-threatening ischaemia patients places BEST-CLI trial into context within real-world setting
A new analysis of chronic limb-threatening ischaemia (CLTI) treatment outcomes was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions (18–20 May, Phoenix, USA), a press release reports. Following the initial…
Government Grand Rounds: Educating through advocacy
Since the initial launch of the Cancer Moonshot in 2016, the cancer community has made tangible progress towards ambitious goals, including accelerating scientific discovery in cancer, fostering greater collaboration and improving data-sharing. Just last year, U.S. President Joe Biden announced…
BASIL-2 points towards endovascular-first revascularization strategy in CLTI patients
A question from Manj Gohel, MD, from Cambridge University Hospitals in Cambridge, England, on what the 2023 Charing Cross (CX) International Symposium audience should take back to their multidisciplinary team meetings from the first-time presentation of BASIL-2 led chief investigator…
Results from PROMISE II pivotal trial published, reinforcing ‘ transformational value’ of deep vein arterialization in no-option CLTI patients
Results from the PROMISE II pivotal trial investigating transcatheter arterialization of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia (CLTI) patients were today published in the New England Journal of Medicine (NEJM). The publication confirmed…
SCVS 2023: Endovascular-first or -only approach to all CLTI patients ‘is not evidence-based care’
Michael S. Conte, MD, one of the foremost experts in the field of peripheral arterial disease (PAD), took attendees of the 2023 annual meeting of the Society for Clinical Vascular Surgery (SCVS) in Miami on a journey through the decades…
Florida hospital targets lingering disparities in limb salvage with region’s first multidisciplinary Limb Preservation Program
This advertorial is sponsored by Tampa General Hospital. Operating in Tampa, Florida, Charles J. Bailey, MD, and his partners in the Division of Vascular Surgery at the University of South Florida see their fair share of preventable amputations. In a…
VESS 2023: pMAC score found to be ‘important predictor’ of CLTI revascularization outcomes
Having observed a strong relationship between calcification and subsequent limb loss, a research team led by investigators from the University of California San Francisco (UCSF) have conducted a single-center, retrospective follow-up extending an initial study evaluating pedal medial arterial calcification…
BioGenCell begins recruitment for clinical trial of stem cell-based treatment for preventing limb amputation
BioGenCell has announced that it is recruiting for an international clinical trial to assess the company’s stem cell-based therapy for chronic limb-threatening ischemia patients who are at risk for limb amputation. The clinical trial is currently taking place in medical…
Early data show ‘dramatic improvement’ in amputation-free survival after initiation of novel ‘Limb Alert’ for acute limb ischemia
This advertorial is sponsored by Tampa General Hospital. In cases of acute limb ischemia (ALI), time is of the essence, says Charles J. Bailey, MD—from the moment a patient first reports to the emergency room (ER) through to the time…
BEST-CLI: Analysis finds correlation between WIfI stage four CLTI and reports of poorer mental health
The BEST-CLI dataset has revealed a correlation between wounds, ischemia and foot infection (WIfI) stage and poorer quality of life due to mental, rather than physical, health for patients with chronic limb threatening ischemia (CLTI). Analyzing complete WIfI data from…